How to Understand and Treat Cancer with Molecular Markers
The Di Bella Method (DBM) Improved Survival, Objective Response and Performance Status in a Retrospective Observational Clinical Study on 122 Cases of Breast Cancer
Sinonasal Diffuse Large B Cell Lymphoma
S Strong 1,2, NS Blencowe 1,2,T Fox 1, C Reid 3, T Crosby 4, H.Ford 5, J M Blazeby 1,2 1 School of Social and Community Medicine, Canynge Hall, University.
59 years old man Hx of stomach adenocarcinoma 20 years ago Hx of chemoradiotherapy cc:gross hematuria.
1 Clinical Stage Cancer Immunotherapy Presentation to Oxford Technology VCT AGM August 26 th 2015 Dr Richard Goodfellow: Joint CEO, Scancell.
BCT for multifocal multicentric breast cancer - Is it contraindicated?
GICS 2012 Final skin toxicity and patient ‑ reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1 st ‑ line metastatic.
Cathy Eng M.D., Salil Sethi M.D., George J.Chang, M.D., Miguel A. Rodriguez-Bigas, M.D., John M. Skibber, M.D., Jianjun Shen Ph.D., Jijiang Zhu Ph.D.,
Optimal Use of Transplant for Myeloma Early-Late-nonablative Koen van Besien, MD, PhD Weill Cornell Medical College.
Primary CNS Lymphoma: focus on role of radiation
Evaluation de la maladie résiduelle dans les lymphomes non hodgkiniens C Tarella, Torino.